For Travere Therapeutics Inc. (TVTX), the year so far has been nothing short of remarkable, with its shares hitting new highs, driven by the success of its oral kidney disease drug, Filspari.
Filspari indicated to slow kidney function decline in adults with a kidney disease called primary immunoglobulin A nephropathy, who are at risk of their disease getting worse, has been on the U.S. market since February 2023. The drug, which was approved under the accelerated approval pathway, was given full FDA approval last September. The drug is also marketed in Europe for the treatment of IgAN by the company's partner CSL Vifor.
For comments and feedback contact: editorial@rttnews.com
Business News
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.